Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Report
April 29, 2021
Axial Spondyloarthritis | Unmet Need | Nonradiographic Axial Spondyloarthritis | US/EU5 | 2021
TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia) are approved for the treatment of nonradiographic axial spondyloarthritis (nr-AxSpA) in…
Report
August 18, 2020
Axial Spondyloarthritis | Access & Reimbursement | US | Ankylosing Spondylitis and Non-Radiographic AxSpA | 2020
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira,…
Report
September 23, 2019
Axial Spondyloarthritis – Current Treatment – Current Treatment: Physician Insights – Axial Spondyloarthritis (EU5)
The axial spondyloarthritis (AxSpA) market dynamics are constantly shifting. The definition of the disease, once limited to ankylosing spondylitis (AS), has expanded beyond those with spinal…
